Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP
Brian T. Hill,
Brad Kahl
Section of Medical Oncology
Siteman Cancer Center
Research output
:
Contribution to journal
›
Review article
›
peer-review
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
R-CHOP
100%
Frontline Therapy
100%
Molecular Features
28%
Single Entity
28%
Clinical Trials
14%
Trial Data
14%
Lymphoma Patients
14%
Novel Therapeutics
14%
Improved Outcomes
14%
Malignancy
14%
Classification System
14%
Patient's Will
14%
Precision Medicine
14%
Advanced Stage
14%
Clinical Investigator
14%
Targeted Agents
14%
Phase III Clinical Trial
14%
Antibody-drug Conjugate
14%
Expert Opinion
14%
Brentuximab Vedotin
14%
Area Cover
14%
Coordinated Efforts
14%
Industry Partners
14%
Frontline Treatment
14%
Molecular Classification
14%
Molecular Assay
14%
CD79B
14%
Multi-omics Study
14%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Clinical Trial
28%
Cancer
14%
Disease
14%
Personalized Medicine
14%
Therapeutic Agent
14%
Antibody-Drug Conjugate
14%
Polatuzumab Vedotin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Clinical Trial
28%
Disease
14%
Antibody Drug Conjugate
14%
Polatuzumab Vedotin
14%